Low resolution surface enhanced raman spectroscopy on sol-gel substrates

摘要

The present invention provides compounds of formula (I) EMI ID=1.1 HE=31 WI=51 LX=803 LY=505 TI=CF PCwhereinBR DL TSIZE=3 DTRDDis aryl or heteroaryl preferably phenyl or pyridine and each of the above groups R may be substituted: DTRSB1/SBDDis hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NRSB4/SBRSB5/SB or cyano; DTRSB2/SBDDcorresponds to CHRSB7/SBRSB8/SB; DTRSB3/SBDDhydrogen, C1-C6 alkyl, halogen; DTRSB7/SBDDis hydrogen, C6-C6 alkenyl or C1-C6 alkyl, and may be substituted by: C1-C6 alkoxy and hydroxy; DTRSB8/SBDDhas the same meaning as RSB7/SB; DTXDDis carbon or nitrogen; preferably nitrogen. DTnDDis 1 or 2; /DL BR with the proviso that 5-(1-ethylpropoxy)-1,2,3,4-tetrahydro-7-methyl-1-(2,4,6-trimethylphenyl)-1,8-naphthyridine is not included. The compounds may be used in the treatment of conditions mediated by corticotropin-releasing factor (CRF). Typically depression, anxiety and irritable or inflammatory bowel disease.